Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 11:58AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.38 Insider Own1.86% Shs Outstand192.42M Perf Week2.42%
Market Cap136.96M Forward P/E- EPS next Y-0.18 Insider Trans0.47% Shs Float188.85M Perf Month-11.03%
Income-72.73M PEG- EPS next Q-0.21 Inst Own17.80% Short Float0.29% Perf Quarter-18.18%
Sales0.00M P/S- EPS this Y-42.69% Inst Trans27.09% Short Ratio10.35 Perf Half Y-35.29%
Book/sh0.73 P/B0.98 EPS next Y77.25% ROA-33.87% Short Interest0.55M Perf Year-55.51%
Cash/sh0.73 P/C0.97 EPS next 5Y21.22% ROE-43.47% 52W Range0.65 - 2.37 Perf YTD-25.29%
Dividend Est.- P/FCF- EPS past 5Y35.36% ROI-50.26% 52W High-69.97% Beta0.72
Dividend TTM- Quick Ratio4.26 Sales past 5Y0.00% Gross Margin- 52W Low9.51% ATR (14)0.06
Dividend Ex-Date- Current Ratio4.26 EPS Y/Y TTM38.93% Oper. Margin0.00% RSI (14)44.08 Volatility6.01% 8.86%
Employees104 Debt/Eq0.10 Sales Y/Y TTM- Profit Margin- Recom1.67 Target Price3.98
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q72.17% Payout- Rel Volume1.21 Prev Close0.68
Sales Surprise656.70% EPS Surprise52.17% Sales Q/Q- EarningsMar 07 AMC Avg Volume53.00K Price0.71
SMA20-2.99% SMA50-10.09% SMA200-34.92% Trades Volume26,299 Change4.42%
Date Action Analyst Rating Change Price Target Change
Jan-04-23Upgrade Societe Generale Hold → Buy
Dec-16-22Downgrade Goldman Neutral → Sell
May-10-22Downgrade Goldman Buy → Neutral $6 → $1.50
Sep-14-21Upgrade Societe Generale Hold → Buy
Jan-22-21Downgrade Societe Generale Hold → Sell
Nov-02-20Upgrade Societe Generale Sell → Hold
Aug-06-20Downgrade Societe Generale Buy → Sell
Aug-05-20Reiterated H.C. Wainwright Buy $25 → $14
Mar-17-20Downgrade Stifel Buy → Hold $18 → $6
Jan-09-20Upgrade Stifel Hold → Buy $10 → $18
Apr-04-24 04:43PM
Mar-08-24 11:01AM
Mar-07-24 10:52PM
04:30PM Loading…
Mar-04-24 04:30PM
Feb-20-24 04:30PM
Jan-16-24 04:30PM
Dec-04-23 04:30PM
Nov-09-23 04:30PM
Nov-06-23 04:30PM
Nov-02-23 04:30PM
Oct-31-23 04:30PM
Oct-27-23 04:30PM
Oct-16-23 02:00AM
04:30PM Loading…
Oct-05-23 04:30PM
Sep-05-23 04:30PM
Jul-31-23 04:25PM
Jul-25-23 04:30PM
Jul-19-23 04:30PM
Jul-10-23 04:30PM
Jun-16-23 04:30PM
Jun-08-23 04:30PM
Jun-06-23 05:00PM
May-10-23 05:30PM
May-09-23 04:30PM
May-04-23 04:30PM
Apr-19-23 05:09PM
Apr-12-23 04:30PM
Mar-24-23 04:30PM
01:30AM Loading…
Mar-13-23 01:30AM
Mar-07-23 04:30PM
Mar-02-23 05:30PM
Feb-27-23 01:30AM
Feb-21-23 04:30PM
Feb-10-23 04:30PM
Jan-23-23 04:30PM
Jan-04-23 04:30PM
Dec-23-22 01:30AM
Dec-08-22 04:30PM
Nov-22-22 04:30PM
Nov-09-22 01:30AM
Nov-03-22 04:30PM
Oct-31-22 04:30PM
Oct-20-22 04:30PM
Oct-03-22 04:30PM
Sep-21-22 05:45PM
Sep-07-22 04:30PM
Sep-02-22 04:30PM
Aug-10-22 04:50PM
Aug-01-22 04:30PM
Jul-27-22 04:30PM
Jul-20-22 04:30PM
Jun-28-22 06:15PM
Jun-16-22 01:30AM
Jun-09-22 02:55AM
Jun-07-22 04:30PM
May-17-22 04:30PM
May-12-22 04:30PM
May-04-22 07:30PM
May-02-22 05:00PM
Apr-25-22 07:30PM
Apr-21-22 04:30PM
Apr-14-22 04:30PM
Mar-14-22 04:30PM
Mar-11-22 04:30PM
Mar-09-22 04:30PM
Mar-03-22 04:15PM
Feb-24-22 04:30PM
Feb-22-22 04:30PM
Feb-14-22 04:30PM
Feb-09-22 04:30PM
Jan-21-22 04:30PM
Jan-18-22 05:38PM
Jan-12-22 04:30PM
Jan-07-22 01:30AM
Dec-20-21 04:15PM
Dec-10-21 04:30PM
Nov-24-21 01:30AM
Nov-04-21 04:30PM
Nov-01-21 03:34PM
Oct-29-21 05:07PM
Oct-27-21 03:35PM
Oct-26-21 04:15PM
Oct-12-21 04:30PM
Sep-08-21 04:00PM
Aug-31-21 01:30AM
Aug-20-21 04:15PM
Aug-09-21 04:30PM
Aug-06-21 04:30PM
Aug-02-21 04:15PM
Jul-26-21 04:30PM
Jul-07-21 04:30PM
Jun-15-21 04:30PM
Jun-02-21 01:30AM
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tasse DanielCHIEF EXECUTIVE OFFICERMar 08 '24Buy0.8317,09414,18817,094Mar 11 04:15 PM
Ndu AdoraDirectorFeb 06 '24Buy0.891,8251,6241,825Feb 08 05:02 PM
Mohideen PharisChief Medical OfficerNov 22 '23Sale1.742,2453,90682,194Dec 19 04:44 PM
MORRIS TIMOTHY EDirectorAug 25 '23Buy1.5212,00018,24012,000Aug 28 04:35 PM
SOLAND DANIEL BDirectorAug 01 '23Buy1.6215,00024,30020,000Aug 03 04:40 PM
Mohideen PharisChief Medical OfficerMay 24 '23Sale3.544691,66049,439Aug 14 04:32 PM